Priavoid is at the forefront of developing innovative treatments for neurodegenerative disorders, utilizing a unique class of compounds known as all-d-peptides. These peptides are designed to target and dissolve harmful protein aggregates, specifically oligomers, which are implicated in diseases such as Alzheimer's and Parkinson's. The company's technology leverages a powerful platform that employs mirror-image phage display selection and various optimization techniques to create lead compounds that can effectively address protein misfolding in the central nervous system. This approach is particularly significant as it aims to tackle the complex and often irreversible processes associated with neurodegeneration.

The therapeutic strategy of Priavoid is characterized by its anti-oligomeric mode of action, which directly targets and neutralizes toxic protein aggregates, thereby preventing their proliferation and the subsequent neuronal damage they cause. By converting these harmful oligomers back into harmless monomers, Priavoid's all-d-peptides not only halt the progression of neurodegenerative diseases but also promote neuronal recovery. This innovative method positions Priavoid as a pioneer in the field, with the potential to develop treatments for a range of conditions linked to protein aggregation, thereby addressing significant unmet medical needs in the realm of neurological health.

Germany

Priavoid is a clinical stage drug development company based in Düsseldorf, Germany. Its therapeutic focus is on protein misfolding disorders in the area of neurodegeneration. Key component of Priavoid's technology is an anti-oligomeric or anti-prionic mode of action, that efficiently and effectively disassembles neurotoxic aggregates by using all-D-peptides.

Priavoid

Company Details